Trials / Unknown
UnknownNCT05672888
Efficacy and Safety of Jaktinib in Patients With COVID-19 Pneumonia.
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- First Affiliated Hospital of Zhejiang University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This was a randomized, double-blind, placebo-controlled parallel study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Jaktinib | 100mg of Jaktinib (given as two 50mg tablets) administered orally Twice daily(BID) with best available treatment. |
| DRUG | Placebo | Placebo (given as two placebo tablets) administered orally BID with best available treatment. |
Timeline
- Start date
- 2023-03-01
- Primary completion
- 2024-01-01
- Completion
- 2024-05-01
- First posted
- 2023-01-05
- Last updated
- 2023-01-17
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05672888. Inclusion in this directory is not an endorsement.